This proposal requests support for a predoctoral and postdoctoral Training Program in Pediatric Hematologic and Oncologic Diseases in the Cincinnati Children's Hospital Medical Center (CCHMC), University of Cincinnati College of Medicine. The underlying premise of this Training Program is that there is a recognition of and need to address the lack of individuals trained in therapeutic research on pediatric hematologic and oncologic diseases who also have a deep appreciation for taking scientific discovery into the clinic. Therefore, the goal of the Training Program is to provide a rigorous understanding of the basic mechanisms of pediatric hematologic and oncologic diseases with a clear translational focus. The program draws heavily upon integrated, m ultidisciplinary, innovative, and established graduate progr ams, Ph.D. postodoctoral training programs, and clinical fellowship training programs from 7 divisions within CCHMC, and involves 21 NIH funded basic scientists and physician-scientists as core mentoring faculty and 5 ancillary clinical faculty. This program enrolls promising young doctoral and postdoctoral (2 predoctoral and 4 postdoctoral) candidates, with a emphasis on minority candidate recruitment, to specialize on one of the hematology and oncology research areas under the direct mentorship of a core mentoring faculty and an ancillary clinical faculty. The areas of research include pediatric hematologic diseases such as leukemia, Fanconi anemia, myeloproliferative disorders, coagulation disorders, and sickle cell disease, immuno- deficiency disorders such as X-linked lymphoproliferative disorder, severe combined immunodeficiencies, Wiskott-Aldrich syndrome, and common variable immunodeficiency, molecular gene therapy strategies treating Fanconi anemia, storage diseases, and sickle cell anemia, and targeted therapies against childhood cancers such as leukemia/lymphoma, neuroblastoma, sarcomas, and musculoskeletal tumors. The selected program faculty share research interests and have a history of collaboration in studies of various blood- related research activities, yet they approach hematologic and oncologic diseases and therapeutics from different perspectives. The use of mouse models combined with patient-directed initiatives represents one of the unique strengths of the Training Program. The grant will include an administrative core consisting of the Principal Investigator, Co-Pi, an Executive Committee, an Admission Committee, an Advisory Committee, and an External Advisory Committee. Training will combine a series of required curriculum including an ethical education course, Experimental Hematology, Immunological Mechanisms of Diseases, Action of Cancer Therapeutics, and Translational Trial Development and Support Laboratory Educational Activities, as well as a number of electives including Biostatistics, Clinical Trials, Functional Genomics, and Seminar in Drug Development. Regular research retreats, data clubs, journal clubs, and seminar series will serve to complement the mentor-directed research activities by further enhancing the knowled ge base of the trainees and cohesiveness of the program. The progress of each trainee will be reviewed and evaluated semi- annually.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL091805-05
Application #
8319442
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Chang, Henry
Project Start
2008-09-01
Project End
2013-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$160,594
Indirect Cost
$11,408
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Guo, F; Li, J; Zhang, S et al. (2014) mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression. Leukemia 28:203-6
Sherrill, J D; Kc, K; Wu, D et al. (2014) Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol 7:718-29
Guo, F; Li, J; Du, W et al. (2013) mTOR regulates DNA damage response through NF-*B-mediated FANCD2 pathway in hematopoietic cells. Leukemia 27:2040-6
Bosco, Emily E; Kumar, Sachin; Marchioni, Filippo et al. (2012) Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation. Chem Biol 19:228-42
Akunuru, Shailaja; Palumbo, Joseph; Zhai, Qihui James et al. (2011) Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. PLoS One 6:e16951
Sherrill, Joseph D; Rothenberg, Marc E (2011) Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies. J Allergy Clin Immunol 128:23-32; quiz 33-4
Privette Vinnedge, L M; McClaine, R; Wagh, P K et al. (2011) The human DEK oncogene stimulates *-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene 30:2741-52
Sherrill, Joseph D; Gao, Pei-Song; Stucke, Emily M et al. (2010) Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol 126:160-5.e3